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Our  understanding  of the antigenic  evolution  of the  human  inﬂuenza  virus  is  chieﬂy  derived  from  exper-
iments  in  which  serum  from  inﬂuenza  infected  ferrets  is  tested  against  panels  of  virus  isolates  in  the
haemagglutination  inhibition  (HI)  assay.  The  interpretation  of these  results  has  been  much  aided  by  the
development  of antigenic  mapping  techniques,  which  suppose  that  the  antigenic  distance  between  two
different  inﬂuenza  viruses  is  directly  proportional  to their  fold-difference  in  titre  in this  assay.  Yet,  anti-
genic distance  is  not  necessarily  the  same  as  cross-protection,  and  high  levels  of  protection  have  been
observed  in humans  against  strains  to  which  they have  low  HI titres.  However,  no  study  has  previously
addressed  the  relationship  between  HI titre  and  cross-protection  in ferrets:  the standard  animal  model.
This study  ﬁlls  this  gap by  analysing  published  data  where  pre-challenge  HI titres are  available  for  indi-
vidual  ferrets,  and  post-challenge  outcomes  have  been  recorded.  Ultimately,  this  work  conﬁrms  that  it
is the  absolute,  rather  than relative,  HI titre that  determines  the  extent  of  immunity  and that  there  is
a  threshold  HI  titre beyond  which  ferrets  are  completely  protected  from  infection.  Nevertheless,  this
titre  is much  higher  in  ferrets  than  has  been  suggested  for humans.  Further,  we are  consequently  able  to
show  that  using  distance  between  strains  within  an  antigenic  map  to predict  cross-protection  between
inﬂuenza  viruses  can  be  misleading.
© 2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
Antigenic evolution is driven by selection for onward trans-
ission: pathogens that can vary their antigenic properties may
reate opportunities to re-infect immunologically experienced
osts. Inﬂuenza is one such pathogen. Many mutants are generated
s it replicates, enough of which have sufﬁciently altered antigenic
roperties to drive recurrent inﬂuenza epidemics in humans. The
urden of these epidemics is such that we take care to vaccinate
hose most at risk from infection, but the pace of antigenic evolu-
ion means that we must expend exhaustive and expensive efforts
o keep the vaccine relevant.
Attempting to understand past, and hence perhaps predict
uture, trajectories of inﬂuenza within antigenic space is of interest,
oth theoretically and practically. The primary (but by no means
nly) tool for this is the haemagglutination inhibition (HI) assay,
 two-fold dilution assay in which the ability of serum to prevent
∗ Corresponding author. Tel.: +44 7889095249.
E-mail address: pwikramaratna@gmail.com (P.S. Wikramaratna).
ttp://dx.doi.org/10.1016/j.vaccine.2015.08.065
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
the agglutination of red blood cells by a particular inﬂuenza virus
is measured. HI titres are generally reported as the reciprocal of
the highest dilution at which agglutination was prevented, with
increasing dilutions indicating higher degrees of antigen binding.
The assay can be criticised because it is often poorly reproducible
between different laboratories [1–3], can only measure the abil-
ity of antibodies to prevent the binding of inﬂuenza to cells that
the virus does not target in vivo, and assumes that ferrets and
humans develop identical cross-reactive immune responses when
challenged with the virus (for more detail see [4–6]). Nevertheless,
it remains the gold standard within inﬂuenza research. Its results
are of critical importance in the process of annual vaccine strain
selection: does the serological response of a ferret (the standard
animal model for human inﬂuenza) vaccinated with strain X sug-
gest that they would be protected against the apparently emergent
strain Y? If not, then the vaccine strain may  need to be updated.
A seminal paper in this area introduced the concept of antigenic
cartography [7]. The authors based their work on the reasoning that
if a ferret that has been previously infected by strain X has an HI
titre of P against X, and a titre of Q against another strain, Y, then the
difference between P and Q tells us something about the proximity
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(Tj, ) as a two  parameter inverse logit function ( = {˛, ˇ}) appliedP.S. Wikramaratna, A. Ramba
f strains X and Y within antigenic space. A two-fold difference in
itre is taken to correspond to 1 unit of distance within this space.
The method employs multi-dimensional scaling to represent
he past antigenic evolution of the virus within a two-dimensional
pace and it is now exceedingly rare for antigenic data to be
resented without an accompanying antigenic map. The original
pplication of these methods to 35 years of human A/H3N2 evo-
ution illustrated that the antigenic evolution of human inﬂuenza
s more punctuated than continuous: viruses cluster together in
ntigenic space for a number of years before suddenly jumping to
 new point and the average distance between the identiﬁed anti-
enic clusters of H3N2 was 4.5 units. Subsequent applications to
/H1N1 and inﬂuenza B have revealed broadly similar patterns,
lthough both appear to ‘jump’ somewhat less energetically [8].
There is, however, a potential difference between antigenicity
literally: the ability to bind to an antigen) and immunogenicity,
r cross-protection. Indeed, a previous analysis of pre-challenge
I titre and its effect on the probability of a serological response
n humans has suggested that a titre against a challenge strain as
ow as 17 may  provide a 50% chance of protection against infection
9,10]. Not only is this titre notably below the normal threshold
or detection in the assay (a titre of 40), but the results also sug-
est that any titre in excess of 200 is almost completely protective.
hus, for example, if antiserum raised against strain X has a homol-
gous HI titre of 5120, but HI titres of only 1280 against strain Y
nd 80 against strain Z, then strains Y and Z are said to be 2 and 6
nits of antigenic distance from X. Contrastingly, in terms of cross-
rotection, the above results suggest not only that infection with
train X provides complete protection against strain Y, but also that
nfection with X provides signiﬁcant protection against strain Z.
Nevertheless, this analysis considers protection from infection
n natural human infection, as opposed to experimental infection in
errets, which is the actual source of almost all antigenic data and
nference. Whether the relationship between HI titre and cross-
rotection is the same in ferrets as it is in humans is therefore
mportant. Although this question has not been previously con-
idered, relevant data has been presented in a number of different
apers and is analysed together here. In particular, we focus on the
esults of a series of experiments in ferrets in the 1970s using the
934 H1N1 and 1968 H3N2 viruses.
An advantage of the present study is that previous work on
ross-protection in humans [9,10] could only try to infer if an indi-
idual had been infected by whether they had a four-fold or greater
ise in HI titre over the course of the ﬂu season (this is the def-
nition of seroconversion [11], but see [12]). Yet cross-protection
etween strains must be related to the reduction in transmission of
ne following prior exposure to the other: something about which
 serological response may  itself tell us little. Fortunately, data on
oth the change in HI titre against a particular strain upon chal-
enge and the viral titre in nasal wash taken after challenge has
een presented for individual ferrets [13–19].
We therefore use this data to estimate the relationship between
I titre and (i) prevention of a serological response and (ii) reduc-
ion of virus production (and hence transmission) in ferrets. We
hen compare our results to those of [9] and consider the con-
equences for our understanding of the antigenic evolution of
nﬂuenza.
. Materials and methods
Using the keywords “immunity”, “inﬂuenza” and “ferret” we
dentiﬁed papers in PubMed that might contain appropriate data.
e then included data from studies where ferrets had pre chal-
enge HI titres against a speciﬁc strain recorded, with post challenge
easurements of HI titre and/or the amount of virus produced inccine 33 (2015) 5380–5385 5381
nasal wash but excluded those ferrets that had been previously vac-
cinated or challenged with a strain that was  HA-mismatched but
NA-matched with the subsequent challenge strain (e.g. previously
challenged with H1N2, measurements provided for subsequent
challenge with H3N2). This resulted in 162 observations from 7
papers [13–19] (Supplementary Table S1).
2.1. Probability of a serological response
Typically, a four-fold rise in HI titre following challenge is taken
as a positive serological response and is indicative of a success-
ful infection; this was  the measure used in the studies analysed
by Coudeville et al. [9]. Following their lead, we start with a base-
line probability (P) that an individual naïve ferret will exhibit a
serological response when challenged with an inﬂuenza strain. To
estimate the reduction in this probability in the presence of HI
antibodies, this baseline probability is combined with a function
(0 ≤ (Tj, ) ≤ 1, where Tj is the HI titre and  is the associated vector
of parameters) such that the probability of a serological response
in a ferret upon exposure is
R
(
P, Tj, 
)
= P ∗ (1 − (Tj, ))
In line with Coudeville et al., we will specify the functional form
associated with (Tj, ) as a two parameter inverse logit function
( = {, }) applied to log-transformed HI titre values:

(
Tj, 
)
= e
(log2(Tj)−)
1 + e(log2(Tj)−)
= 1 − 1
1 + e(log2(Tj)−)
and so
R(P, Tj, , ) =
P
1 + e(log2(Tj)−)
Coudeville et al. point out that  corresponds to the titre that
halves the amount of virus produced (it is a location parameter
for the curve) whilst  determines its steepness [9]. The main
reason for choosing a two-parameter inverse logit function, as
opposed to a different smooth increasing function, is that it leads
to a straightforward method of constructing conﬁdence intervals
for the probability of protection. It is also the standard ‘link func-
tion’ for binary data so represents a natural choice here. For more
information see [20].
2.2. Reduction in virus production in undiluted nasal wash
In these papers, the amount of virus produced in undiluted nasal
wash is reported 3 days after challenge as 10X EID50/ml (50% egg
infectious dose per ml). In this paper we  will model the effect of HI
titres on reducing the size of this exponent.
The model estimates the amount of virus, V, which an individual
ferret will produce when inoculated with inﬂuenza. In the absence
of HI antibodies, the average amount, ,  corresponds to a base-
line, log10 EID50/ml. This value may  be reduced in the presence of
HI antibodies however, and is therefore combined with a function
describing the effect of HI titre (0 ≤ (Tj, ) ≤ 1, where Tj is the HI
titre and  is the associated vector of parameters). Thus, the average
amount of amount of virus produced by an exposed ferret is
(	, Tj, ) = 	(1 − (Tj, ))
As above, we will specify the functional form associated withto log-transformed HI titre values:

(
Tj, ˛, ˇ
)
= e
ˇ(log2(Tj)−˛)
1 + eˇ(log2(Tj)−˛)
= 1 − 1
1 + eˇ(log2(Tj)−˛)
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Table 1
Parameter estimates for model of effect of HI titre on probability of a serological
response.
Quantiles Parameter estimate
  ˚ P
2.5% 7.41 0.71 0.95
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Table 2
Parameter estimates for model of effect of HI titre on reduction of virus production
in  undiluted nasal wash.
Quantiles Parameter estimate
 ˛  ˇ 	 

2.5% 6.62 0.54 4.76 0.89
50% 7.31 0.85 4.98 1.01
97.5%  7.83 1.00 5.07 1.06
Fig. 1. Estimated effect of pre-existing HI titre on probability of serological response.
The solid black line shows the posterior median value, with the 95% credible interval
shaded in grey.
Fig. 2. Estimated effect of pre-existing HI titre on extent of nasal shedding. This is
the reduction in the average amount of nasal shedding predicted by a particular HI50% 8.23 1.23 0.99
97.5%  8.99 2.15 1.00
As before,  ˛ corresponds to the titre that halves the amount of
irus produced (it is a location parameter for the curve) whilst ˇ
etermines its steepness.
Finally, we anticipate that not all ferrets will respond identically:
he actual amount of virus produced will vary around some mean.
n particular, following inspection of the data (see Supplementary
igure S1), we suppose that it is lognormally distributed around 
ith standard deviation 
 (which is to be estimated). And so, the
mount of virus produced by a ferret upon exposure is
(
	, Tj, ˛, ˇ, 

)
∼N
(
	
1 + eˇ(log2(Tj)−˛)
, 

)
.3. Censored data
An important consideration is that reported HI titres represent
nterval censored data. If a titre is reported as ‘X’ then the true titre
n fact lies in the interval [X, 2X), whereas if it is reported as ‘<Y’
hen it lies on the interval [1,Y). We  therefore treat the HI titres as
atent variables that exist somewhere in the appropriate interval
as opposed to assigning them an arbitrary value somewhere within
his interval). The titre is reported as ‘>5120′ for one observation.
trictly speaking this means that the true titre lies on the interval
5120, ∞),  but because this titre is already very large we  choose to
odel it as a latent variable on (5120, 10.240) for practical reasons.
There also appears to be a detection limit for the amount of virus
roduced in nasal wash, which is recorded as 0.7log10 EID50/ml in
ne study [21] (NB No ferrets in this study were actually included in
he analysis here because HI titres against the actual challenge virus
ere not recorded). In many instances, viral titres are reported as
0′ rather than as ‘<Y’ but we believe that the former is shorthand
or the latter. For all viral titres reported as 0, we have therefore
hosen to model the titre as a latent variable that exists somewhere
n [0,0.7).
.4. Parameter estimation
Markov Chain Monte Carlo (MCMC) methods were imple-
ented on the models speciﬁed above, using the software package
rjags’ [22].
Posterior summary statistics were based on 3 Markov chains of
0,000 lengths after a burn-in of 40,000 iterations. Convergence
as assessed using Gelman–Rubin statistics [23].
For each of the unknown parameters specifying the shape of a
urve (˛, ˇ, 	 , , ) we chose a standard diffuse prior ∼  (0.0001,
.0001) (so that these parameters could take on any value in (0,
)), but for P chose a prior ∼ U(0,1).
. Results
Supplementary Figures S2 and S3 and the Gelman–Rubin statis-
ics suggest that the Markov chains and burn-in period are
ufﬁciently long for the posterior statistics to be meaningful.
Parameter estimates are presented in Tables 1 and 2; we esti-
ate the 50% protective titre against seroconversion as 300 (95% CItitre, as compared to the expected titre when the HI titre is undetectable. The solid
black line shows the posterior median value, with the 95% credible interval shaded
in grey.
170–508) and the titre that leads to a 50% drop in log10 virus titre in
nasal wash as 159 (95% CI 98–228). The respective curves are shown
in Figs. 1 and 2. Notably, there is a threshold HI titre at which unde-
tectable amounts of virus are produced in nasal wash (for titres in
excess of 640 the viral titre drops below 100.7; see Fig. 2). Further
increases in HI titre beyond this threshold are therefore irrelevant
with respect to these measures.
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Fig. 3. Predicted viral titre based on pre-existing HI titre. The solid red line shows
the median level of protection predicted by pre-existing HI titre, while the shaded
region shows the 95% CI. The data on which the analysis is based are represented by
black circles. There is some uncertainty in the exact HI measurement for all ferrets
as the pre-challenge HI titre of each ferret is interval censored data; what is shown
here is the median posterior estimate of the true HI titre. Similarly, for ferrets whose
viral titre was  described as undetectable (“<5” or “<10”), shown here is the median
posterior estimate of the true viral titre. In other words, the black dots represent a
best  guess of the true titre for each ferret, given the prior knowledge of the interval
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Fig. 4. Relationship between distance in antigenic map  and estimated protection.
Bedford et al. [8] produced a map  of H3N2 based on ∼10,000 measurements of the
HI  titre of ferret sera raised against a particular strain against different antigens.
For  each of these measurements we show (i) the Euclidean distance between the
position of each sera and antigen in the map and (ii) the extent of protection (deﬁned
as  reduction in nasal shedding) that we would predict based on the observed HI
titre (blue points). We also show the results of a beta regression of map  distance
against protection (solid green line; shaded green area corresponds to 95% CI). (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to  the web  version of this article.)
Fig. 5. Protective effect through time. For each sera-antigen pair analysed in Bedford
et al., this shows how the average protection (deﬁned as reduction in nasal shedding)
predicted by the HI titre of serum against antigen is affected by the of number of years
difference between the date of isolation of the serum and the date of isolation of the
antigen (positive numbers mean that the antigen was collected after the serum).
Comparisons between sera and antigen that were isolated close together in time
4. Discussionn  which their HI titre lies, the observed viral titre and the inferred relationship
etween pre-existing HI titre and viral titre.
Unsurprisingly, higher HI titres result in both a lower probabil-
ty of a serological response and a lower volume of virus shedding.
ur results suggest, however, that the effect on virus shedding is
ore potent. This makes intuitive sense: seroconversion signals
hat the pre-existing immune response was insufﬁcient to clear the
nfection and so might be triggered only by large amounts of virus
roduction. Nevertheless, the credible intervals for both curves
verlap and so a deﬁnitive statement is impossible. One reason
or the width of these credible intervals is that data in the appar-
ntly critical region is comparatively sparse: there are relatively
ew ferrets with intermediate pre-challenge HI titres (Fig. 3).
The parameter 
 is necessary to capture the full extent of vari-
bility in the amount of virus produced in nasal wash by ferrets
Fig. 3), which presumably reﬂects experimental noise, such as the
arying resistance of individual ferrets to infection. Coupled with
he general lack of ferrets whose HI titres are in the critical region,
his indicates a need for more experiments to be carried out in
mmunologically experienced ferrets to better characterise these
elationships.
Generally, these results suggest that we should not treat fold-
ifference in homologous and heterologous titre (i.e. position
ithin current antigenic maps) as the primary measure of the
ross-protection of different inﬂuenza viruses. Instead, we should
onsider the absolute value of a heterologous titre. The impor-
ance of this concept is illustrated in Fig. 4: in maps where virus
o-ordinates are derived from a function of fold-difference in titre,
istance is a generally poor predictor of cross-protection. Of course,
here is a correlation between the two as you would expect, but
lmost anything is possible for a distance of 5 units in the map. Fur-
her, as shown in Supplementary Figure S4, there is often extensive
ross-protection between different antigenic clusters as deﬁned in
xisting maps, and also between viruses isolated many years apart
Fig. 5). These results nevertheless support the concept that expo-
ure to a currently circulating virus will provide very high levels
f protection for the next 2–3 years, but the size of the conﬁdenceare much more common than between those isolated far apart in time and so this
represents the median and 50% CI for predicted protection based on a bootstrap of
1000 samples for each measurement.
intervals means that we  cannot rule out signiﬁcant levels of pro-
tection over a much longer period.To try to improve our understanding of the antigenic evolution
of the human inﬂuenza virus, we  have estimated the effect of HI
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The research leading to these results has received funding from384 P.S. Wikramaratna, A. Ramba
itre on both (i) the probability of a ferret exhibiting a serological
esponse to infection and (ii) the reduction of virus produced in
erret nasal wash 3 days after challenge.
Both these measures should in some way correlate with
he probability of onward transmission. Normally, a serological
esponse is taken as evidence that a successful infection (i.e. viral
eplication) has taken place, and that (further) mobilisation of
he adaptive immune system was required for its termination. Its
bsence is strongly suggestive that only limited viral replication
ook place, but the extent of this limitation (and its consequences
or onward transmission) is poorly deﬁned. The second measure
onsidered here explicitly captures the extent of the restrictions
mposed on the virus. Both measures suggest that there is a strong
igmoidal relationship between protection and HI titre and that it
s the absolute value of a titre that determines the extent of protec-
ion. Thus, a doubled HI titre is not necessarily twice as biologically
ffective; this may  also extend to other similar immunological
ssays.
Given that we routinely draw inferences about cross-protection
nd antigenic similarity between human inﬂuenza viruses based
n the results of the HI assay in ferrets, it is imperative to under-
tand the connection between ferret and human HI results. Both
f the curves shown here are further to the right than the curve
eported by Coudeville et al. for the prevention of a serological
esponse in humans [9]; indeed they report a 50% protective titre
gainst seroconversion of 17 (95% CI 10–29). It is probable that the
noculum used in the experiments on ferrets is much larger than
hat encountered by a human during an average seasonal exposure:
hus much higher levels of circulating antibody may  be required
o prevent seroconversion (and infection more generally) in labo-
atory ferrets than in wild humans. A similar reason (high levels
f virus shedding) was proposed to explain why, in a study pro-
ection against inﬂuenza infection in Hong Kong households [24],
he 50% protective titre was found to be signiﬁcantly higher than
hat observed by Coudeville et al. [9] (260 (95% CI 30–2009) for
/H3N2 and 255 (95% CI 62–917) for A/H1N1). However, it could
lso be that the RT-PCR analysis of nasal and throat swabs employed
y [24] is more sensitive than seroconversion to inﬂuenza infec-
ion. Although an inverse relationship between the amount of virus
roduced and the likelihood of onward transmission is intuitive,
here is no data to support the speciﬁc choice made here (that the
ercent reduction in viral titre on a log scale corresponds to an
quivalent drop in infectiousness). A particular concern is that the
mount of virus produced after 3 days may  not be entirely repre-
entative of the virus’s actual transmission potential. Experiments
25] with A(H1N1)pdm09 have shown that the amount of virus in
erret nasal wash is maximised 1–2 days after challenge. At this
ime, the animals are asymptomatic but nevertheless capable of
nward transmission. The amount of virus in nasal wash decreases
hereafter, and no onward transmission is possible by day 5 even
hough virus can be found in nasal wash and ferrets are symp-
omatic. Further, although the experiments of [25] used a different
ssay (the number of Plaque Forming Units per ml  of nasal wash
PFU/ml]) to measure viral titre, its value on day 5 was still around
log10 PFU/ml. Given that no transmission was observed at this
ime, this may  in itself imply that there is a threshold amount of
irus that must be produced for there to be any chance of onward
ransmission. If true, the simple relationship used here may  be
nappropriate to describe the relationship between viral titre and
nfectiousness.
A critical point with regard to this work’s utility is that it pro-
ides a potential bridge from a single ferret exposure to a single
uman exposure. Of course, reality is much more complex: the
atural human immune proﬁle is dictated by repeat exposure to
everal inﬂuenza strains across the course of a lifetime. Further-
ore, protection in both ferrets and humans is likely mediatedaccine 33 (2015) 5380–5385
by more than just whatever we  measure in the HI assay [26,27].
This work does however emphasise that fairly low HI titres can
be enough to indicate cross-protection. A consequence of this is
that cross-protection can be observed across different antigenic
clusters but how then do inﬂuenza viruses manage to cause reg-
ular epidemics, and why is vaccination with the previous year’s
dominantly circulating strain not more effective [28]? One  possi-
bility is that although vaccination of a naïve individual with last
season’s dominant strain may  be enough to protect them against
the next wave of viruses, the same may  not be true in someone
who is immunologically experienced. If pre-existing antibodies are
enough to prevent replication of the vaccine strain, then there is no
stimulus to produce a de novo response that could protect against
the next antigenic cluster. This is a form of original antigenic sin [29]
and is consistent with recently published results suggesting that
vaccine effectiveness is higher in those who  have not been recently
vaccinated [30]. Similarly, perhaps the next wave of viruses are not
selected for their ability to escape immunity arising from infec-
tion in the current epidemic, but rather for their ability to escape
from immunity in individuals that was  generated several epidemics
previously [31].
One issue with the results presented here is that much of the
data analysed in this study has come from ferrets on which various
vaccines were being tested. It is likely that vaccinated individuals
may  exhibit HI titres that are inﬂated relative to their true level
of protection [28], and, alongside a high challenge dose, this is
another potential reason why (i) the curves we report here are
further to the right than the equivalent in humans (as the fer-
rets are less protected than suggested by HI) and (ii) we  observe
signiﬁcant variability among ferrets (as the precise effect could
be vaccine-dependent). At the same time, since the type of vac-
cine may  confound the use of seroconversion as a useful indicator
of exposure [32], this study is strengthened by our simultaneous
examination of viral titre in ferrets.
Another issue is that this data represents responses in ferrets
solely to 1968 A/H3N2 and 1934 A/H1N1 viruses: it is conceivable
that the response curves could vary among viruses or subtypes
(e.g., see [33]). Nevertheless, there is not sufﬁcient data avail-
able to test this here. In particular, although many papers present
data on serological responses in ferrets, more recent authors tend
to report this data as an average across similarly treated fer-
rets (usually 3). Yet, even though the mean and range of titres
across 3 ferrets might be reported, the reported mean titre is
often incompatible with a third measurement inside this range;
thus these data cannot be analysed because they are not self-
consistent. Coupled with information on the apparent variability
of responses within individual ferrets, this emphasises a need
to report data on individual ferrets alongside aggregated data in
future.
Overall, this work shows that absolute HI titres are more impor-
tant than relative ones for determining cross protection. However,
there is an urgent need for more and better data – more measure-
ments from ferrets with intermediate HI titres, and against a wider
panel of viruses – to reﬁne our understanding of this important rela-
tionship and better relate results in ferrets to outcomes in humans.
Nor should we forget that other aspects of the immune response
will contribute to protection in both.
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